Direct oral anticoagulants (DOACs) have become the standard of care for acute and long-
term therapy for venous thromboembolism (VTE) due to their efficacy and safety profiles. The …

Background: Anticoagulation (AC) is the cornerstone of treatment for venous
thromboembolism (VTE). Direct oral anticoagulants (DOACs) have become the standard of …

Background: Use of direct-acting oral anticoagulants (DOACs) in morbidly obese (BMI> 40
kg/m 2) patients for venous thromboembolism (VTE) treatment is not fully understood …

There is limited data evaluating clinical outcomes of rivaroxaban versus warfarin in obese
patients with venous thromboembolism (VTE). Our objective was to evaluate the …

Venous thromboembolism (VTE) is a leading cause of morbidity and mortality worldwide.
Appropriate anticoagulation is crucial in the treatment and prevention of recurrent VTE …

Background Direct oral anticoagulants (DOAC) use remains challenging in obese patients
treated for Venous-Thrombo-Embolism (VTE) due to the paucity of prospective and …

Background Rivaroxaban, a direct oral anticoagulant (DOAC), has been shown to be an
efficacious and safe agent for treatment and secondary prevention of thromboembolism …

Introduction Limited data exist on direct-acting oral anticoagulants in morbidly obese
patients with venous thromboembolism (VTE). We compared clinical and health/economic …

Study Objective Studies on the use of direct oral anticoagulants (DOACs) in obese patients
are limited. Current guidelines advise against DOAC use in patients with a body weight …

Background: Obesity is a well-known risk factor for venous thromboembolism (VTE),
however, obese patients are under-represented in clinical trials (1; 2). Four direct oral …